News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
News Major UK market breakthrough for Keytruda in lung cancer But funding will last only two years on CDF.
News CEO Meek looks to boost Ipsen with drug acquisitions Could French biotech snap up remaining rights to pancreatic cancer drug?
News Pfizer chief suggests no BMS bid - for now Ian Read won't quash rumours that his company Pfizer could swoop for vulnerable Bristol-Myers Squibb - but says it won't make any major acquisitions
News Sales of Keytruda double ahead of key lung cancer decision FDA to make decision on wider lung cancer use within a week.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.